Patient characteristics
| Characteristic . | No. . |
|---|---|
| Sex | |
| Men | 20 |
| Women | 6 |
| Age, y | |
| Median | 60 |
| Range | 46-76 |
| ECOG performance status | |
| 0 | 7 |
| 1 | 18 |
| ND | 1 |
| Rai stage | |
| I-II | 7 |
| III-IV | 19 |
| Prior regimens | |
| Median | 4 |
| Range | 2-12 |
| Fludarabine | 26 |
| Refractory to fludarabine | 22 |
| Alkylating agents | 25 |
| Rituximab | 24 |
| Alemtuzumab | 11 |
| Characteristic . | No. . |
|---|---|
| Sex | |
| Men | 20 |
| Women | 6 |
| Age, y | |
| Median | 60 |
| Range | 46-76 |
| ECOG performance status | |
| 0 | 7 |
| 1 | 18 |
| ND | 1 |
| Rai stage | |
| I-II | 7 |
| III-IV | 19 |
| Prior regimens | |
| Median | 4 |
| Range | 2-12 |
| Fludarabine | 26 |
| Refractory to fludarabine | 22 |
| Alkylating agents | 25 |
| Rituximab | 24 |
| Alemtuzumab | 11 |
ECOG indicates Eastern Cooperative Oncology Group; and ND, not documented.